| SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Marcela TOMÍŠKOVÁ, Lenka JAKUBÍKOVÁ, Jana ŠPELDOVÁ, Bohdan KADLEC, Ondřej VENCLÍČEK, Monika BRATOVÁ, Andrea BENEJOVÁ a Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno. Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, roč. 79, č. 3, s. 88-94. ISSN 1213-810X. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1555856,
author = {Skřičková, Jana and Chloupková, Renata and Tomíšková, Marcela and Jakubíková, Lenka and Špeldová, Jana and Kadlec, Bohdan and Venclíček, Ondřej and Bratová, Monika and Benejová, Andrea and Merta, Zdeněk},
article_location = {Praha},
article_number = {3},
keywords = {Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment},
language = {cze},
issn = {1213-810X},
journal = {Studia pneumologica et phthiseologica},
title = {Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno},
url = {https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d},
volume = {79},
year = {2019}
}
TY - JOUR
ID - 1555856
AU - Skřičková, Jana - Chloupková, Renata - Tomíšková, Marcela - Jakubíková, Lenka - Špeldová, Jana - Kadlec, Bohdan - Venclíček, Ondřej - Bratová, Monika - Benejová, Andrea - Merta, Zdeněk
PY - 2019
TI - Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno
JF - Studia pneumologica et phthiseologica
VL - 79
IS - 3
SP - 88-94
EP - 88-94
PB - Trios s.r.o.
SN - 1213810X
KW - Advanced non-small cell lung cancer
KW - Bevacizumab
KW - Carboplatin
KW - Oral vinorelbine
KW - Treatment
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d
L2 - https://www.scopus.com/record/display.uri?eid=2-s2.0-85071030604&origin=resultslist&sort=plf-f&src=s&st1=L%c3%a9%c4%8dba+bevacizumabem+v+kombinaci+s+karboplatinou&st2=&sid=7905ba79f0ebb11e19b49592ec5472c1&sot=b&sdt=b&sl=62&s=TITLE-ABS-KEY%28L%c3%a9%c4%8d
N2 - For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.
ER -
SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Marcela TOMÍŠKOVÁ, Lenka JAKUBÍKOVÁ, Jana ŠPELDOVÁ, Bohdan KADLEC, Ondřej VENCLÍČEK, Monika BRATOVÁ, Andrea BENEJOVÁ a Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno. \textit{Studia pneumologica et phthiseologica}. Praha: Trios s.r.o., 2019, roč.~79, č.~3, s.~88-94. ISSN~1213-810X.
|
